Psoriatic Arthritis | Unmet Need | US/EU | 2021

Although tumor necrosis factor-alpha (TNF-α) inhibitors remain the preferred treatments for psoriatic arthritis (PsA) following failure of conventional disease-modifying antirheumatic drugs (cDMARDs), the more recently introduced interleukin-17 (IL-17) inhibitors Cosentyx and Taltz and the oral therapies Otezla and Xeljanz have chipped away at TNF-α inhibitors’ patient share. Understanding the underlying unmet need in the treatment of PsA, as well as the factors that can differentiate similar products from one another, can determine the success of an agent in this competitive space. This report presents the unmet needs in PsA treatment based on the results of surveys of U.S. and European rheumatologists and dermatologists and provides the tools to make strategic decisions and assessments regarding the PsA therapy market.

QUESTIONS ANSWERED

• How do Novartis’s Cosentyx, Eli Lilly’s Taltz, Amgen’s Otezla, and Pfizer’s Xeljanz compare with other agents for PsA in terms of efficacy, safety, convenience of administration, and access to reimbursement?
• How do American College of Rheumatology (ACR) response, Psoriasis Area and Severity Index (PASI) score, Health Assessment Questionnaire-Disability Index (HAQ-DI) improvement, risk of malignancy, and rate of infection affect rheumatologists’ and dermatologists’ prescribing decisions for PsA?
• How do U.S. and European rheumatologists and dermatologists view the value of oral therapies for PsA?
• What are the prevailing areas of unmet need and opportunity in the PsA market?

PRODUCT DESCRIPTION

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by our experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 62 U.S. and 30 European rheumatologists and dermatologists fielded in January 2021

Key companies: AbbVie, Amgen, Pfizer, Janssen, Novartis, Eli Lilly

Key drugs: Humira, Enbrel, Stelara, Cosentyx, Taltz, Otezla, Xeljanz